A Proteomics-Based Analysis of Blood Biomarkers for the Diagnosis of COPD Acute Exacerbation

Overview

Journal Int J Chron Obstruct Pulmon Dis

Publisher Dove Medical Press

Specialty Pulmonary Medicine

Date 2021 Jun 11

PMID 34113087

Citations 8

Authors

Soo Han Kim

Hee-Sung Ahn

Jin-Soo Park

Jeonghun Yeom

Jiyoung Yu

Kyunggon Kim

Yeon-Mok Oh

Affiliations

Soon will be listed here.

Abstract

Purpose: The identification of blood biomarkers to diagnose acute exacerbation of chronic obstructive pulmonary disease (AECOPD) will have clinical utility. Here, we used a proteomics-based approach to identify biomarkers capable of identifying AECOPD.

Patients And Methods: This prospective, single-center pilot study enrolled 12 patients who came to Asan Medical Center (South Korea) via the outpatient clinic or emergency department with symptoms of AECOPD and were follow-up in the outpatient clinic during convalescence between 2015 and 2017. Paired blood samples collected from each patient during the treatment naïve AECOPD and convalescence stages were analyzed. A sequential window acquisition of all theoretical fragmentation spectra-mass spectrometry (SWATH-MS)-based proteome analysis was performed and a subset of the data were verified by ELISA.

Results: The SWATH-MS analysis identified 226 plasma proteins across all samples examined. The median coefficient of variation for triplicate technical replicates of each sample was 1.13 ± 1.38%, indicating high precision of the technique. Fold-change and paired -test analyses revealed that 14 proteins were present at higher levels in the AECOPD samples than in the convalescence samples. A gene ontology analysis revealed that these proteins are involved in the acute-phase response. A total of 15 proteins were present at higher levels during the recovery (convalescence) stage than during the acute exacerbation phase, and gene ontology analysis revealed that these proteins are related to lipid metabolism and transport. Verification of the SWATH-MS data was performed using ELISAs for three proteins that were up-regulated in AECOPD, namely, LBP, ORM2, and SERPINA3. Among them, SERPINA3 (p = 0.005) was up-regulated significantly in AECOPD compared with the convalescence state.

Conclusion: Potential plasma biomarkers of AECOPD were discovered using the SWATH-MS proteomics method, and functional molecular associations were investigated. SERPINA3 could be a promising diagnostic biomarker for the early identification and tracking of AECOPD.

Citing Articles

Proteomic Blood Profiles Obtained by Totally Blind Biological Clustering in Stable and Exacerbated COPD Patients.

Enriquez-Rodriguez C, Pascual-Guardia S, Casadevall C, Caguana-Velez O, Rodriguez-Chiaradia D, Barreiro E Cells. 2024; 13(10.

PMID: 38786086 PMC: 11119172. DOI: 10.3390/cells13100866.

Prognostic Biomarkers Based on Proteomic Technology in COPD: A Recent Review.

Fang H, Liu Y, Yang Q, Han S, Zhang H Int J Chron Obstruct Pulmon Dis. 2023; 18:1353-1365.

PMID: 37408604 PMC: 10319291. DOI: 10.2147/COPD.S410387.

Guidance Value of Procalcitonin Detection in Selecting Switching Points for Sequential Therapy in Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease Complicated by Respiratory Failure.

Ding F, Liu W, Wang H, Wang W, Yang C Int J Chron Obstruct Pulmon Dis. 2022; 17:2693-2699.

PMID: 36281227 PMC: 9587698. DOI: 10.2147/COPD.S366028.

Predictive Value of Serum Markers SFRP1 and CC16 in Acute Exacerbation of Chronic Obstructive Pulmonary Disease.

He Y, Yu J, Zhu D, Gao J Evid Based Complement Alternat Med. 2022; 2022:6488935.

PMID: 35958937 PMC: 9363185. DOI: 10.1155/2022/6488935.

Data-Independent Acquisition Enables Robust Quantification of 400 Proteins in Non-Depleted Canine Plasma.

Ravuri H, Noor Z, Mills P, Satake N, Sadowski P Proteomes. 2022; 10(1).

PMID: 35324581 PMC: 8953371. DOI: 10.3390/proteomes10010009.

References

Leung J, Chen V, Hollander Z, Dai D, Tebbutt S, Aaron S . COPD Exacerbation Biomarkers Validated Using Multiple Reaction Monitoring Mass Spectrometry. PLoS One. 2016; 11(8):e0161129. PMC: 4985129. DOI: 10.1371/journal.pone.0161129. View

Chan S, Selemidis S, Bozinovski S, Vlahos R . Pathobiological mechanisms underlying metabolic syndrome (MetS) in chronic obstructive pulmonary disease (COPD): clinical significance and therapeutic strategies. Pharmacol Ther. 2019; 198:160-188. PMC: 7112632. DOI: 10.1016/j.pharmthera.2019.02.013. View

Hoofnagle A, Whiteaker J, Carr S, Kuhn E, Liu T, Massoni S . Recommendations for the Generation, Quantification, Storage, and Handling of Peptides Used for Mass Spectrometry-Based Assays. Clin Chem. 2016; 62(1):48-69. PMC: 4830481. DOI: 10.1373/clinchem.2015.250563. View

Zhu J, Li R, Tiselius E, Roudi R, Teghararian O, Suo C . Immunotherapy (excluding checkpoint inhibitors) for stage I to III non-small cell lung cancer treated with surgery or radiotherapy with curative intent. Cochrane Database Syst Rev. 2017; 12:CD011300. PMC: 6486009. DOI: 10.1002/14651858.CD011300.pub2. View

Mouronte-Roibas C, Leiro-Fernandez V, Fernandez-Villar A, Botana-Rial M, Ramos-Hernandez C, Ruano-Ravina A . COPD, emphysema and the onset of lung cancer. A systematic review. Cancer Lett. 2016; 382(2):240-244. DOI: 10.1016/j.canlet.2016.09.002. View

Zhu H, Zhou W, Wan Y, Ge K, Lu J, Jia C . Downregulation of orosomucoid 2 acts as a prognostic factor associated with cancer-promoting pathways in liver cancer. World J Gastroenterol. 2020; 26(8):804-817. PMC: 7052533. DOI: 10.3748/wjg.v26.i8.804. View

Trigueros Carrero J . How should we define and classify exacerbations in chronic obstructive pulmonary disease?. Expert Rev Respir Med. 2013; 7(2 Suppl):33-41. DOI: 10.1586/ers.13.16. View

Escher C, Reiter L, MacLean B, Ossola R, Herzog F, Chilton J . Using iRT, a normalized retention time for more targeted measurement of peptides. Proteomics. 2012; 12(8):1111-21. PMC: 3918884. DOI: 10.1002/pmic.201100463. View

Mohsenzadegan M, Peng R, Roudi R . Dendritic cell/cytokine-induced killer cell-based immunotherapy in lung cancer: What we know and future landscape. J Cell Physiol. 2019; 235(1):74-86. DOI: 10.1002/jcp.28977. View

10.

Perera W, Hurst J, Wilkinson T, Sapsford R, Mullerova H, Donaldson G . Inflammatory changes, recovery and recurrence at COPD exacerbation. Eur Respir J. 2006; 29(3):527-34. DOI: 10.1183/09031936.00092506. View

11.

Dentener M, Creutzberg E, Schols A, Mantovani A, Vant Veer C, Buurman W . Systemic anti-inflammatory mediators in COPD: increase in soluble interleukin 1 receptor II during treatment of exacerbations. Thorax. 2001; 56(9):721-6. PMC: 1746133. DOI: 10.1136/thorax.56.9.721. View

12.

Zhu T, Zhu Y, Xuan Y, Gao H, Cai X, Piersma S . DPHL: A DIA Pan-human Protein Mass Spectrometry Library for Robust Biomarker Discovery. Genomics Proteomics Bioinformatics. 2020; 18(2):104-119. PMC: 7646093. DOI: 10.1016/j.gpb.2019.11.008. View

13.

Regan E, Hersh C, Castaldi P, DeMeo D, Silverman E, Crapo J . Omics and the Search for Blood Biomarkers in Chronic Obstructive Pulmonary Disease. Insights from COPDGene. Am J Respir Cell Mol Biol. 2019; 61(2):143-149. PMC: 6670029. DOI: 10.1165/rcmb.2018-0245PS. View

14.

Prins H, Duijkers R, van der Valk P, Schoorl M, Daniels J, van der Werf T . CRP-guided antibiotic treatment in acute exacerbations of COPD in hospital admissions. Eur Respir J. 2019; 53(5). DOI: 10.1183/13993003.02014-2018. View

15.

Uysal P, Uzun H . Relationship Between Circulating Serpina3g, Matrix Metalloproteinase-9, and Tissue Inhibitor of Metalloproteinase-1 and -2 with Chronic Obstructive Pulmonary Disease Severity. Biomolecules. 2019; 9(2). PMC: 6406460. DOI: 10.3390/biom9020062. View

16.

Regueiro V, Campos M, Morey P, Sauleda J, Agusti A, Garmendia J . Lipopolysaccharide-binding protein and CD14 are increased in the bronchoalveolar lavage fluid of smokers. Eur Respir J. 2008; 33(2):273-81. DOI: 10.1183/09031936.00087708. View

17.

Chen H, Wang D, Bai C, Wang X . Proteomics-based biomarkers in chronic obstructive pulmonary disease. J Proteome Res. 2010; 9(6):2798-808. DOI: 10.1021/pr100063r. View

18.

Wedzicha J, Seemungal T . COPD exacerbations: defining their cause and prevention. Lancet. 2007; 370(9589):786-96. PMC: 7134993. DOI: 10.1016/S0140-6736(07)61382-8. View

19.

HaileMariam M, Eguez R, Singh H, Bekele S, Ameni G, Pieper R . S-Trap, an Ultrafast Sample-Preparation Approach for Shotgun Proteomics. J Proteome Res. 2018; 17(9):2917-2924. DOI: 10.1021/acs.jproteome.8b00505. View

20.

Vogelmeier C, Criner G, Martinez F, Anzueto A, Barnes P, Bourbeau J . Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary. Eur Respir J. 2017; 49(3). DOI: 10.1183/13993003.00214-2017. View